Nampt/PBEF/visfatin serum levels: A new biomarker for retinal blood vessel occlusions

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 611-618

  Kaja, Simon ^a   Shah, Anna A ^a   Haji, Shamim A ^a   Patel, Krishna B ^a   Naumchuk, Yuliya ^a   Zabaneh, Alexander ^a   Gerdes, Bryan C ^a   Kunjukunju, Nancy ^a   Sabates, Nelson R ^a   Cassell, Michael A ^a   Lord, Ron K ^a   Pikey, Kevin P ^a   Poulose, Abraham ^a   Koulen, Peter ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Nampt; Nicotinamide phosphoribosyltransferase; PBEF; Pre B cell colony enhancing factor; Retina; Retinal artery occlusion; Retinal vein occlusion; Vasculature; Visfatin

Indexed keywords

NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CASE CONTROL STUDY; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HEMIRETINAL VEIN OCCLUSION; HUMAN; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROTEIN EXPRESSION; RETINA BLOOD VESSEL OCCLUSION; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; VERY ELDERLY; VISUAL IMPAIRMENT;

EID: 84929580956     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S80784     Document Type: Article

References (31)

1. Mirshahi A, Feltgen N, Hansen LL, Hattenbach LO. Retinal vascular occlusions: an interdisciplinary challenge. Dtsch Arztebl Int. 2008;105(26):474–479.
2. Keane PA, Sadda SR. Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab. Clin Ophthalmol. 2011;5:771–781.
3. Sartori MT, Barbar S, Donà A, et al. Risk factors, antithrombotic treat­ment and outcome in retinal vein occlusion: an age-related prospective cohort study. Eur J Haematol. 2013;90(5):426–433.
4. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 2008;38(12):904–910.
5. Sadda S, Danis RP, Pappuru RR, et al. Vascular changes in eyes treated with dexamethasone intravitreal implant for macular edema after retinal vein occlusion. Ophthalmology. 2013;120(7):1423–1431.
6. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-1101.e.
7. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–809.
8. Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2013;1:CD009510.
9. Merkoudis N, Granstam E. Treatment of macular edema associated with retinal vein occlusion using sustained-release dexamethasone implants in a clinical setting. Eur J Ophthalmol. 2013;23(4):558–563.
10. Sun Z, Lei H, Zhang Z. Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev. 2013;25(4):433–442.
11. Zabka TS, Singh J, Dhawan P, et al. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicol Sci. 2015;144(1):163–172.
12. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des. 2009;15(1):20–28.
13. Niven JE, Laughlin SB. Energy limitation as a selective pressure on the evolution of sensory systems. J Exp Biol. 2008;211(pt 11):1792–1804.
14. Wong-Riley MT. Energy metabolism of the visual system. Eye Brain. 2010;2:99–116.
15. Falk MJ, Zhang Q, Nakamaru-Ogiso E, et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet. 2012;44(9):1040–1045.
16. Perrault I, Hanein S, Zanlonghi X, et al. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat Genet. 2012;44(9):975–977.
17. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab. 2007;92(12):4783–4791.
18. Se Fum Wong S, Kuei JJ, Prasad N, et al. A simple method for DNA isolation from clotted blood extricated rapidly from serum separator tubes. Clin Chem. 2007;53(3):522–524.
19. Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med. 2005;171(4):361–370.
20. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29(1):31–35.
21. Axelsson J, Witasp A, Carrero JJ, et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis. 2007;49(2):237–244.
22. Senolt L, Kryštůfková O, Hulejová H, et al. The level of serum visfa­tin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine. 2011;55(1):116–121.
23. Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC. Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respira­tory distress syndrome. Crit Care Med. 2007;35(5):1290–1295.
24. Liu Y, Shao Y, Yu B, Sun L, Lv F. Association of PBEF gene polymorphisms with acute lung injury, sepsis, and pneumonia in a northeastern Chinese population. Clin Chem Lab Med. 2012;50(11):1917–1922.
25. Lee K, Huh JW, Lim CM, Koh Y, Hong SB. Clinical role of serum pre-B cell colony-enhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome. Scand J Infect Dis. 2013;45(10):760–765.
26. Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr. 2012;6(2):120–124.
27. Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide phos­phoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009;105(5):481–491.
28. Bi J, Li H, Ye SQ, Ding S. Pre-B-cell colony-enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models. J Neurochem. 2012;120(2):334–346.
29. Wang P, Guan YF, Du H, Zhai QW, Su DF, Miao CY. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy. 2012;8(1):77–87.
30. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013;110(6):E517–E525.
31. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13(4):388–391.